| BOSVX | VISVX | BOSVX / VISVX | |
| Total Expense Ratio | 0.47 | 0.19 | 247% |
| Annual Report Gross Expense Ratio | 0.64 | 0.19 | 337% |
| Fund Existence | 15 years | 28 years | - |
| Gain YTD | 25.124 | 15.731 | 160% |
| Front Load | N/A | N/A | - |
| Min. Initial Investment | 0 | 0 | - |
| Min. Initial Investment IRA | N/A | N/A | - |
| Net Assets | 1.31B | 67.8B | 2% |
| Annual Yield % from dividends | 1.24 | 1.65 | 75% |
| Returns for 1 year | 33.75 | 23.82 | 142% |
| Returns for 3 years | 25.45 | 42.73 | 60% |
| Returns for 5 years | 15.91 | 46.24 | 34% |
| Returns for 10 years | 69.67 | 135.70 | 51% |
| 1 Day | |||
|---|---|---|---|
| MFs / NAME | Price $ | Chg $ | Chg % |
| BQLCX | 23.42 | 0.17 | +0.73% |
| Bright Rock Quality Large Cap Instl | |||
| GSPAX | 20.13 | 0.12 | +0.60% |
| Goldman Sachs US Eq Div and Premium A | |||
| GSIMX | 24.30 | N/A | N/A |
| Goldman Sachs GQG Ptnrs Intl Opps Instl | |||
| CCWIX | 21.73 | -0.15 | -0.69% |
| Baird Chautauqua International Gr Instl | |||
| RYOIX | 86.56 | -2.00 | -2.26% |
| Rydex Biotechnology Inv | |||